SOLIGENIX, INC. — Director's Dealing 2018

Jul 25, 2018

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: SOLIGENIX, INC. (SNGX)
CIK: 0000812796
Period of Report: 2018-07-02

Reporting Person: Pearson Mark E. (Director, 10% Owner)

Holdings (Non-Derivative)

Security	Shares	Ownership
COMMON STOCK	2330000	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
WARRANT (RIGHT TO BUY)	$2.25	2022-01-02	COMMON STOCK (932000)		Indirect

Footnotes

F1: The warrant currently is exercisable, subject to a blocker provision that prevents the holder from exercising the warrant if such holder would beneficially own in excess of 4.99% of the issuer's common stock following such exercise.

F2: These securities are held by Altamont Pharmaceutical Holdings, LLC, a company for which the reporting person serves as general partner and chief executive officer. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or any other purpose.